Search Results

You are looking at 321 - 330 of 498 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher K. Bichakjian, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mohammed Kashani-Sabet, Julie R. Lange, Anne Lind, Lainie Martin, Mary C. Martini, Scott K. Pruitt, Merrick I. Ross, Stephen F. Sener, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Jeffrey Weber, and Michael K. Wong

. 95 Agarwala SS Keilholz U Hogg D . Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract] . J Clin Oncol 2007 ; 25 ( Supp 1 ): Abstract 8510

Full access

Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma

Talia Golan and Pascal Hammel

2020 ; 70 : 7 – 30 . 31912902 10.3322/caac.21590 3. Goldstein D , El-Maraghi RH , Hammel P , nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial . J Natl Cancer Inst 2015 ; 107

Full access

Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Nilofer Azad, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Hisham Hussan, William Jeck, Kimberly L. Johung, Nora Joseph, Natalie Kirilcuk, Smitha Krishnamurthi, Jennifer Maratt, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Eden Stotsky-Himelfarb, Anna Tavakkoli, Christopher G. Willett, Grant Williams, Frankie Algieri, Lisa Gurski, and Katie Stehman

with paclitaxel has been noted as the preferred regimen for first-line treatment of metastatic anal cancer by the NCCN Panel. 232 In this trial, 91 patients with previously untreated, unresectable, locally recurrent or metastatic anal squamous cell

Full access

Cancer- and Chemotherapy-Induced Anemia

George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic, and Alva B. Weir III

lbl.pdf . Accessed January 25, 2012 . 29 Untch M Fasching PA Bauerfeind I . PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard

Full access

Abstracts From the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™

Phase I Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed by Standard Chemoradiation in HPV-Negative or High-Risk HPV-Positive Locally Advanced-Stage III/IVa/IVb HNSCC Christine H. Chung, MD a ; Hyunseok Kang, MD a ; Ana Kiess, MD

Full access

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Robert I Haddad, Lindsay Bischoff, Douglas Ball, Victor Bernet, Erik Blomain, Naifa Lamki Busaidy, Michael Campbell, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney S. Goldner, Theresa Guo, Megan Haymart, Shelby Holt, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Dominick M. Lamonica, Susan Mandel, Stephanie Markovina, Bryan McIver, Christopher D. Raeburn, Rod Rezaee, John A. Ridge, Mara Y. Roth, Randall P. Scheri, Jatin P. Shah, Jennifer A. Sipos, Rebecca Sippel, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Michael Yeh, Carly J. Cassara, and Susan Darlow

– 176 selpercatinib or pralsetinib are options for RET fusion-positive disease; 112 , 113 and pembrolizumab is an option for TMB-H (≥10 mut/Mb) disease. 124 Other recommended regimens include paclitaxel and doxorubicin monotherapies. 160

Full access

Head and Neck Cancers

David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara A. Burtness, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr., Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, Giuseppe Sanguineti, David E. Schuller, Jatin P. Shah, Sharon Spencer, Andy Trotti III, Randal S. Weber, Gregory T. Wolf, and Frank Worden

cisplatin/5-FU used in induction trials of the 1980s and 1990s, and the related meta-analyses. Results from 3 phase III trials, which compared induction cisplatin plus infusional 5-FU with or without the addition of a taxane (docetaxel or paclitaxel

Full access

Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™

study was comprised of 112 patients with stage III (72 patients; 64.2%) and IV cancers (40 patients; 35.8%). All patients underwent 3–4 cycles of NACT (paclitaxel and carboplatin) after diagnosis confirmation via cytology or biopsy. Serum CA-125 and HE4

Full access

Additional Abstracts from the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™

of Dose-dense Paclitaxel in the Adjuvant Treatment of Breast Cancer Has Equal Toxicity Profile to Weekly Paclitaxel Mohamed Alsharedi, MD; Jennifer Dotson, DO; Nabiha Elmsherghi, MD; Todd Gress, MD, MPH; and Mria Tirona, MD, FACP Edwards

Full access

Non–Small Cell Lung Cancer, Version 1.2015

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

treatment include cisplatin/etoposide, cisplatin/vinblastine, and carboplatin/paclitaxel (see “Chemotherapy Regimens Used with Radiation Therapy” online, in these guidelines, at NCCN.org [NSCL-E]). 185 , 187 , 194 , 195 For non-squamous NSCLC, other